Ugochukwu Nwokoro, MD
Internal Medicine · Dayton, OHNPI 1013919778
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Chiesi USA, Inc. at 51.5% of the total. Reporting peaked in 2023 at $4,568 and has fallen 75.8% since, to $1,106 in 2025. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $66.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$4K
- AstraZeneca$739
- Dexcom, Inc.$555
- Pfizer$424
- Johnson & Johnson$373
- Boehringer Ingelheim$371
- plus $1K from 21 others
Across 103 payments — averaging $9409.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$223K
- Genentech, Inc.$191K
- Astrazeneca UK Limited$135K
- Verona Pharma, Inc.$124K
- Bristol Myers Squibb$117K
- Chiesi USA, Inc.$87K
- plus $92K from 3 others
What the payments were for
- Travel & lodging$3,78148%
- Food & beverage$3,82349%
- Education$2273%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 5 | $4,033 |
| AstraZeneca | 9 | $739 |
| Dexcom, Inc. | 16 | $555 |
| Pfizer | 17 | $424 |
| Johnson & Johnson | 14 | $373 |
| Boehringer Ingelheim | 3 | $371 |
| Lilly USA, LLC | 3 | $157 |
| Bayer | 8 | $152 |
| Astellas Pharma US Inc | 5 | $149 |
| Renalytix AI, Inc. | 1 | $124 |
| Abbott | 6 | $122 |
| Novo Nordisk | 4 | $113 |
| Scilex Pharmaceuticals Inc. | 5 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| BETA Bionics, Inc. | 2 | $63 |
| Exact Sciences | 2 | $47 |
| Grifols USA, LLC | 2 | $38 |
| Corcept Therapeutics | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Valeritas, Inc. | 2 | $30 |
| Novartis | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| AbbVie | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,831 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $144,901 |
| EliquisApixaban | 109 | $84,195 |
| TrulicityDulaglutide | 50 | $81,834 |
| OzempicSemaglutide | 53 | $72,665 |
| FarxigaDapagliflozin Propanediol | 77 | $67,551 |
| LinzessLinaclotide | 26 | $23,017 |
| MounjaroTirzepatide | 13 | $15,597 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $14,844 |
| KerendiaFinerenone | 15 | $13,372 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,808 |
| Bydureon BciseExenatide Microspheres | 14 | $11,296 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $10,328 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 284 | $9,918 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $5,416 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $371 | $144,901126 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $157 | $97,43163 claims |
| PfizerEliquis | $424 | $84,195109 claims |
| Novo NordiskOzempic | $113 | $72,66553 claims |
| AstraZenecaFarxiga, Symbicort | $739 | $72,56095 claims |
| AbbVieLinzess | $21 | $23,01726 claims |
| BayerKerendia | $152 | $13,37215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Dayton
- Richard KimDayton$326K
- Isaac HumphreyDayton$224K
- Celine JacobDayton$126K
- Miguel PariloDayton$84K
- Richard SaxenDayton$38K
- Mamle AnimDayton$37K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.